Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8459)
All Articles published online
|
Publishing Process of This Article
|
Jun 8, 2015 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Chen KW, Ou TM, Hsu CW, Horng CT, Lee CC, Tsai YY, Tsai CC, Liou YS, Yang CC, Hsueh CW, Kuo WH. Current systemic treatment of hepatocellular carcinoma: A review of the literature. World J Hepatol 2015; 7(10): 1412-1420 [PMID: 26052386 DOI: 10.4254/wjh.v7.i10.1412] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v7/i10/1412.htm |
| Number | Citing Articles |
| 1 |
Xuan Jing, Hongping Liang, Xiangrong Cui, Chongyang Han, Chonghua Hao, Kai Huo. Long noncoding RNA CCAT2 can predict metastasis and a poor prognosis: A meta-analysis. Clinica Chimica Acta 2017; 468: 159 doi: 10.1016/j.cca.2017.03.003
|
| 2 |
Michael L Caparelli, Nathan J Roberts, Timothy S Braverman, Robert M Stevens, Edward R Broun, Shyam Allamaneni. Metastatic recurrence to a solitary lymph node four years after hepatic lobectomy for primary hepatocellular carcinoma. World Journal of Hepatology 2016; 8(23): 994-998 doi: 10.4254/wjh.v8.i23.994
|
| 3 |
Julie K. Heimbach, Laura M. Kulik, Richard S. Finn, Claude B. Sirlin, Michael M. Abecassis, Lewis R. Roberts, Andrew X. Zhu, M. Hassan Murad, Jorge A. Marrero. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67(1): 358 doi: 10.1002/hep.29086
|
| 4 |
Jinhong Guo, Wenjie Yan, Hao Duan, Diandian Wang, Yaxi Zhou, Duo Feng, Yue Zheng, Shiqi Zhou, Gaigai Liu, Xia Qin. Therapeutic Effects of Natural Products on Liver Cancer and Their Potential Mechanisms. Nutrients 2024; 16(11): 1642 doi: 10.3390/nu16111642
|
| 5 |
Ayse Banu Demir, Elif Baris, Umay Bengi Kaner, Hani Alotaibi, Nese Atabey, Ahmet Koc. Toll-interacting protein may affect doxorubicin resistance in hepatocellular carcinoma cell lines. Molecular Biology Reports 2023; 50(10): 8551 doi: 10.1007/s11033-023-08737-2
|
| 6 |
Sandro Nuciforo, Isabel Fofana, Matthias S. Matter, Tanja Blumer, Diego Calabrese, Tujana Boldanova, Salvatore Piscuoglio, Stefan Wieland, Femke Ringnalda, Gerald Schwank, Luigi M. Terracciano, Charlotte K.Y. Ng, Markus H. Heim. Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies. Cell Reports 2018; 24(5): 1363 doi: 10.1016/j.celrep.2018.07.001
|
| 7 |
Bang-Bin Chen, Chao-Yu Hsu, Chih-Wei Yu, Po-Chin Liang, Chiun Hsu, Chih-Hung Hsu, Ann-Lii Cheng, Tiffany Ting-Fang Shih. Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma. European Radiology 2017; 27(7): 3069 doi: 10.1007/s00330-016-4670-2
|
| 8 |
Zhenluo Jiang, Lili Shen, Shuwei Wang, Shengdong Wu, Yaoren Hu, Junming Guo, Liyun Fu. Hsa_circ_0028502 and hsa_circ_0076251 are potential novel biomarkers for hepatocellular carcinoma. Cancer Medicine 2019; 8(17): 7278 doi: 10.1002/cam4.2584
|
| 9 |
Mohamed M. Tawfik, Nourhan Eissa, Fayez Althobaiti, Eman Fayad, Ali H. Abu Almaaty. Nomad Jellyfish Rhopilema nomadica Venom Induces Apoptotic Cell Death and Cell Cycle Arrest in Human Hepatocellular Carcinoma HepG2 Cells. Molecules 2021; 26(17): 5185 doi: 10.3390/molecules26175185
|
| 10 |
Justin Hartke, Matthew Johnson, Marwan Ghabril. The diagnosis and treatment of hepatocellular carcinoma. Seminars in Diagnostic Pathology 2017; 34(2): 153 doi: 10.1053/j.semdp.2016.12.011
|
| 11 |
Zhenluo Jiang, Shuwei Wang, Jiancheng Jin, Sheng Ying, Zhigang Chen, Dedong Zhu, Bingxiu Xiao, Yaoren Hu, Yunsong Qian, Ting Cai, Liyun Fu. The clinical significance of serum chitinase 3‐like 1 in hepatitis B–related chronic liver diseases. Journal of Clinical Laboratory Analysis 2020; 34(5) doi: 10.1002/jcla.23200
|
| 12 |
Annie K Hung, Jennifer Guy. Hepatocellular carcinoma in the elderly: Meta-analysis and systematic literature review. World Journal of Gastroenterology 2015; 21(42): 12197-12210 doi: 10.3748/wjg.v21.i42.12197
|
| 13 |
Xianwei Zhang, Hu Zhou, Wei Jing, Ping Luo, Shili Qiu, Xuefang Liu, Man Zhu, Chunzi Liang, Mingxia Yu, Jiancheng Tu. The Circular RNA hsa_circ_0001445 Regulates the Proliferation and Migration of Hepatocellular Carcinoma and May Serve as a Diagnostic Biomarker. Disease Markers 2018; 2018: 1 doi: 10.1155/2018/3073467
|
| 14 |
Muhammad Raza Shah, Muhammad Imran, Shafi Ullah. Nanocarriers for Cancer Diagnosis and Targeted Chemotherapy. 2019; : 79 doi: 10.1016/B978-0-12-816773-1.00004-3
|
| 15 |
Mahfoozur Rahman, Waleed H Almalki, Majed Alrobaian, Jawed Iqbal, Saad Alghamdi, Khalid S Alharbi, Nabil K Alruwaili, Abdul Hafeez, Adil Shaharyar, Tanuja Singh, Mohammad Waris, Vikas Kumar, Sarwar Beg. Nanocarriers-loaded with natural actives as newer therapeutic interventions for treatment of hepatocellular carcinoma. Expert Opinion on Drug Delivery 2021; 18(4): 489 doi: 10.1080/17425247.2021.1854223
|
| 16 |
Mingang He, Wenchao Gu, Yang Gao, Ying Liu, Jie Liu, Zengjun Li. Molecular subtypes and a prognostic model for hepatocellular carcinoma based on immune- and immunogenic cell death-related lncRNAs. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.1043827
|
| 17 |
Peng-Sheng Yi, Min Huang, Ming Zhang, Liangliang Xu, Ming-Qing Xu. Comparison of Transarterial Chemoembolization Combined with Radiofrequency Ablation Therapy versus Surgical Resection for Early Hepatocellular Carcinoma. The American Surgeon™ 2018; 84(2): 282 doi: 10.1177/000313481808400238
|
| 18 |
Shashank Kumar, Abhay Kumar Pandey. Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma. Current Oncology 2023; 30(2): 1363 doi: 10.3390/curroncol30020105
|
| 19 |
Yuee Cai, Yingqi Xu, Hon Fai Chan, Xiaobin Fang, Chengwei He, Meiwan Chen. Glycyrrhetinic Acid Mediated Drug Delivery Carriers for Hepatocellular Carcinoma Therapy. Molecular Pharmaceutics 2016; 13(3): 699 doi: 10.1021/acs.molpharmaceut.5b00677
|
| 20 |
Xing Wang, Haisheng Guo, Weixin Liu, Chunmei Yang, Lei Yang, Dongguan Wang, Xunguo Wang. Effects of siRNA-Mediated Knockdown of HDAC1 on the Biological Behavior of Esophageal Carcinoma Cell Lines. Medical Science Monitor 2016; 22: 1291 doi: 10.12659/MSM.895853
|
| 21 |
Mingfang Wu, Bolin Lian, Yiping Deng, Ziqi Feng, Chen Zhong, Weiwei Wu, Yannian Huang, Lingling Wang, Chang Zu, Xiuhua Zhao. Resveratrol-loaded glycyrrhizic acid-conjugated human serum albumin nanoparticles wrapping resveratrol nanoparticles: Preparation, characterization, and targeting effect on liver tumors. Journal of Biomaterials Applications 2017; 32(2): 191 doi: 10.1177/0885328217713357
|
| 22 |
Wafaa M. Rashed, Mohamed Ahmed Mohamed Kandeil, Mohamed O. Mahmoud, Sameera Ezzat. Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview. Journal of the Egyptian National Cancer Institute 2020; 32(1) doi: 10.1186/s43046-020-0016-x
|
| 23 |
Fan-Yun Kong, Xiao Wei, Kai Zhou, Wei Hu, Yan-Bo Kou, Hong-Juan You, Xiao-Mei Liu, Kui-Yang Zheng, Ren-Xian Tang, Jason Blackard. Bioinformatics Analysis Reveals Distinct Molecular Characteristics of Hepatitis B-Related Hepatocellular Carcinomas from Very Early to Advanced Barcelona Clinic Liver Cancer Stages. PLOS ONE 2016; 11(7): e0158286 doi: 10.1371/journal.pone.0158286
|
| 24 |
Chao Meng, Xiaomin Shen, Wentao Jiang. Potential biomarkers of HCC based on gene expression and DNA methylation profiles. Oncology Letters 2018; doi: 10.3892/ol.2018.9020
|
| 25 |
I-Tao Huang, Bijay Dhungel, Ritu Shrestha, Kim R. Bridle, Darrell H. G. Crawford, Aparna Jayachandran, Jason C Steel. Spotlight on Bortezomib: potential in the treatment of hepatocellular carcinoma. Expert Opinion on Investigational Drugs 2019; 28(1): 7 doi: 10.1080/13543784.2019.1551359
|
| 26 |
Lumin Chen, Jihong Sun, Xiaoming Yang. Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status. Cancer Letters 2016; 370(1): 78 doi: 10.1016/j.canlet.2015.09.020
|
| 27 |
Meng-Hua Chung, Shu-Yi Wang, Chia-Chin Lin. Symptom Clusters and Impact of Fatigue and Sleep Disturbance on Symptom Experiences of Hepatoma Patients in Taiwan. Cancer Nursing 2017; 40(5): 403 doi: 10.1097/NCC.0000000000000417
|
| 28 |
Niki Vassilaki, Efseveia Frakolaki. Virus–host interactions under hypoxia. Microbes and Infection 2017; 19(3): 193 doi: 10.1016/j.micinf.2016.10.004
|
| 29 |
Umesh Tharehalli, Michael Svinarenko, André Lechel. Remodelling and Improvements in Organoid Technology to Study Liver Carcinogenesis in a Dish. Stem Cells International 2019; 2019: 1 doi: 10.1155/2019/3831213
|
| 30 |
Mingao Zhu. Inhibitory effects of bortezomib in a subcutaneous tumor model of H22 mouse hepatocarcinoma cells. Pathology - Research and Practice 2019; 215(6): 152388 doi: 10.1016/j.prp.2019.03.017
|
| 31 |
Daniel Hughes, Aron Hughes, Bilal Al-Sarireh. Hepatocellular carcinoma’s 100 most influential manuscripts: A bibliometric analysis. International Journal of Hepatobiliary and Pancreatic Diseases 2019; 9(2): 1 doi: 10.5348/100083Z04DH2019OA
|
| 32 |
Chao Wu, Hongwei Kan, Min Hu, Xin Liu, Alex Boye, Yufeng Jiang, Jiajun Wu, Jiyu Wang, Xiaochuan Yang, Yan Yang. Compound Astragalus and Salvia miltiorrhiza extract inhibits hepatocarcinogenesis via modulating TGF‑β/TβR and Imp7/8. Experimental and Therapeutic Medicine 2018; doi: 10.3892/etm.2018.6292
|
| 33 |
Mengxiao Chen, Huaying Huang, Yujin Pan, Zhenzhen Li, Si Ouyang, Changjing Ren, Qiang Zhao. Preparation of layering-structured magnetic fluorescent liposomes and labeling of HepG2 cells. Bio-Medical Materials and Engineering 2022; 33(2): 147 doi: 10.3233/BME-228000
|
| 34 |
Ping Luo, Sanyun Wu, Yalan Yu, Xinliang Ming, Shuo Li, Xuelan Zuo, Jiancheng Tu. Current Status and Perspective Biomarkers in AFP Negative HCC: Towards Screening for and Diagnosing Hepatocellular Carcinoma at an Earlier Stage. Pathology & Oncology Research 2020; 26(2): 599 doi: 10.1007/s12253-019-00585-5
|
| 35 |
Yu-Lan Li, Xiao-Min Zhu, Hong Liang, Chris Orvig, Zhen-Feng Chen. Recent Advances in Asialoglycoprotein Receptor and Glycyrrhetinic Acid Receptor-Mediated and/or pH-Responsive Hepatocellular Carcinoma- Targeted Drug Delivery. Current Medicinal Chemistry 2021; 28(8): 1508 doi: 10.2174/0929867327666200505085756
|
| 36 |
Ping Huang, Yu Hua Zhang, Xiao Wei Zheng, Yu Jia Liu, Hong Zhang, Luo Fang, Yi Wen Zhang, Chang Yang, Khairul Islam, Chao Wang, Hua Naranmandura. Phenylarsine oxide (PAO) induces apoptosis in HepG2 cellsviaROS-mediated mitochondria and ER-stress dependent signaling pathways. Metallomics 2017; 9(12): 1756 doi: 10.1039/C7MT00179G
|
| 37 |
Wei Jing, Shanshan Gao, Man Zhu, Ping Luo, Xuan Jing, Hongyan Chai, Jiancheng Tu. Potential diagnostic value of lncRNA SPRY4-IT1 in hepatocellular carcinoma. Oncology Reports 2016; 36(2): 1085 doi: 10.3892/or.2016.4859
|
| 38 |
Wenbin Ding, Haixia Yang, Shenchu Gong, Weixiang Shi, Jing Xiao, Jinhua Gu, Yilang Wang, Bosheng He. Candidate miRNAs and pathogenesis investigation for hepatocellular carcinoma based on bioinformatics analysis. Oncology Letters 2017; 13(5): 3409 doi: 10.3892/ol.2017.5913
|
| 39 |
Houyong Long, Xingjun Guo, Shen Qiao, Qingxing Huang. Tumor LXR Expression is a Prognostic Marker for Patients with Hepatocellular Carcinoma. Pathology & Oncology Research 2018; 24(2): 339 doi: 10.1007/s12253-017-0249-8
|
| 40 |
Jiale Ju, Yinghua Wu, Wen He, Lin Zhan, Xuelian Yin, Junfeng Zhang, Yuxi Zhang, Li Qiu, Pir Muhammad, Rui L. Reis, Chenchen Li. Nanocarriers for Active Ingredients of Chinese Medicine (AIFCM) Used in Gastrointestinal Cancer Therapy. Journal of Biomedical Nanotechnology 2022; 18(10): 2279 doi: 10.1166/jbn.2022.3446
|
| 41 |
Christos Damaskos, Nikolaos Garmpis, Dimitrios Dimitroulis, Anna Garmpi, Iason Psilopatis, Panagiotis Sarantis, Evangelos Koustas, Prodromos Kanavidis, Dionysios Prevezanos, Gregory Kouraklis, Michail V. Karamouzis, Georgios Marinos, Konstantinos Kontzoglou, Efstathios A. Antoniou. Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead—A Systematic Review. International Journal of Molecular Sciences 2022; 23(22): 14117 doi: 10.3390/ijms232214117
|
| 42 |
Guang Song, Hong-Xia Cao, Shao-Xin Yao, Cang-Tuo Li. Abnormal expression of WIF1 in hepatocellular carcinoma cells and its regulating effect on invasion and metastasis factors of TIMP-3 and caveolin-1 of hepatocellular carcinoma. Asian Pacific Journal of Tropical Medicine 2015; 8(11): 958 doi: 10.1016/j.apjtm.2015.10.007
|
| 43 |
Meiwan Chen, Xingzhi Zhou, Ruie Chen, Junlin Wang, Richard D. Ye, Yitao Wang, Chuanbin Wu, Ram I. Mahato. Nano-carriers for delivery and targeting of active ingredients of Chinese medicine for hepatocellular carcinoma therapy. Materials Today 2019; 25: 66 doi: 10.1016/j.mattod.2018.10.040
|